设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

2018 年第 1 期 第 13 卷

紫杉醇腹腔灌注和静脉滴注双途径给药模式二线治疗胃癌伴恶性腹腔积液的效果

作者:毕兰青朱凡张勤英时建明

英文作者:

单位:215000江苏省苏州市立医院北区肿瘤科

英文单位:

关键词:胃肿瘤;恶性腹腔积液;腹腔灌注;静脉滴注;紫杉醇

英文关键词:

  • 摘要:
  • 【摘要】目的    分析紫杉醇腹腔灌注和静脉滴注双途径给药模式二线治疗胃癌伴恶性腹腔积液的效果。方法    选择2014年1月至2015年12月江苏省苏州市立医院北区肿瘤科收治的晚期胃癌伴恶性腹腔积液患者70例。患者完全随机分为观察组(36例)和对照组(34例)。对照组给予静脉滴注紫杉醇;观察组采用腹腔灌注和静脉滴注紫杉醇的双途径给药模式;2组均联合口服替吉奥80 mg/m2,2次/d,连服14 d,化疗后休息7 d,21 d为1个疗程。2组至少治疗2个疗程。比较2组患者近期疗效、长期疗效和不良反应情况。结果    观察组患者近期有效率明显高于对照组[69.4%(25/36)比44.1%(15/34)],差异有统计学意义(χ2=4.58,P<0.05)。观察组中位随访时间、中位无进展生存期、中位生存时间和1年生存率与对照组比较,差异均无统计学意义(均P>0.05)。观察组白细胞减少、血小板减少、贫血、恶心呕吐、口腔黏膜炎、肝功能异常、腹痛腹泻、肌肉关节痛发生率与对照组比较,差异均无统计学意义(均P>0.05)。结论    紫杉醇腹腔灌注和静脉滴注双途径给药模式治疗胃癌伴恶性腹腔积液的近期疗效较好,不良反应轻,可耐受。

  • Effects of second-line intraperitoneal and intravenous chemotherapy with paclitaxel on gastric cancer complicated with malignant ascites

    Bi Lanqing, Zhu Fan, Zhang Qinying, Shi Jianming

    Department of Oncology, North Branch of Suzhou Municipal Hospital, Jiangsu Province, Suzhou 215000, China

    Corresponding author: Bi Lanqing, Email: yangchen1132@163.com

    【Abstract】Objective     To investigate effects of second-line intraperitoneal and intravenous chemotherapy with paclitaxel on gastric cancer complicated with malignant ascites. Methods    Totally 70 gastric cancer patients with malignant ascites from January 2014 to December 2015 in Suzhou Municipal Hospital were randomly divided into observation group(36 cases) and control group(34 cases). The control group had intravenous chemotherapy with paclitaxel; the observation group had intraperitoneal and intravenous chemotherapy with paclitaxel. Both groups took tegafur 80 mg/m2, 2 times/d, 1-14 d, 21 d for 1 course, and they were treated for 2 courses. Short-, long-term efficacy and adverse reactions were analyzed. Results    The short-term effective rate in observation group was significantly higher than that in control group[69.4%(25/36) vs 44.1%(15/34))](χ2=4.58,P<0.05). Median follow-up time, median progression free survival time, median survival time and 1-year survival rate in observation group had no significant differences compared to those in control group(P>0.05). There were no significant differences of incidences of leukocytopenia, thrombocytopenia, hypohemia, nausea and vomiting, oral mucositis, liver dysfunction, abdominal pain and diarrhea, muscle and joint pain between groups(P>0.05). Conclusion    Intravenous and intraperitoneal chemotherapy with paclitaxel have good short-term efficacy and tolerable side effects on patients with gastric cancer complicated with malignant ascites.

    【Key words】Stomach neoplasms;Malignant ascites;Intraperitoneal infusion;Intravenous drip;Paclitaxel


copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭
Baidu
map